Samantha Pearce
Equibles does not estimate personal net worth.
About Samantha Pearce
Jazz Pharmaceuticals plc reported in an 8-K filed October 9, 2026 that Samantha Pearce retired as Executive Vice President, Chief Commercial Officer. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $6,076,127 for Samantha Pearce in fiscal 2025, including a base salary of $695,673. Disclosed compensation is on record for 2 fiscal years. Samantha Pearce has spoken on 1 investor event across 1 company, most recently for Jazz Pharmaceuticals plc on September 10, 2026. The companies whose calls Samantha Pearce spoke on are classified in the Healthcare sector.
“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
Samantha Pearce on recent calls
“Well, thank you for inviting us and thanks for joining us today, everybody. Absolutely. So I think I would just start by really reiterating and highlighting the strong commercial performance over the last few quarters.”
Affiliation history
-
Jazz Pharmaceuticals plc (JAZZ)
Proxy statement
Start not stated–2026-10-09
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President, Chief Commercial Officer | $695,673 | $6,076,127 |
| 2024 | Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President, CCO | $619,794 | $4,464,254 |